Anti-PD-L1 antibody has been developed for canine cancer treatment, and its promising efficacy against malignant melanoma and undifferentiated sarcoma was reported in a pilot clinical study (14). The gene discussed is CD274; the disease is undifferentiated (embryonal) sarcoma.